ATLANTA and CHICAGO, Oct. 5, 2012 /PRNewswire/ – At the 2012 Congress of Neurological Surgeons (CNS) Annual Meeting, October 6-10, at McCormick Place (Chicago, Ill.), Elekta (booth #620) will reveal compelling new innovations for Leksell Gamma Knife® that promise to enhance information management.
Leksell Gamma Knife Registry will debut asa highly valuable software solution for research, treatment optimization and the future development of evidence-based medicine. By providing efficient and consistent data management, the registry helps physicians ensure the accuracy and consistency of treatment. It also provides patient outcomes for effective long-term analysis.
Leksell Gamma Knife Registry is powered by MOSAIQ®, Elekta's comprehensive Oncology Information System. Connectivity between Leksell Gamma Knife and MOSAIQ (in Leksell GammaPlan 10.2) ensures a better flow of patient care and saves valuable time and resources. In addition to importing patient information, users also can interface with billing systems, import appointment scheduling, import lab results and export lab orders.
In addition, Elekta will highlight characteristics of Leksell Gamma Knife® Perfexion™ that separate the system from other radiosurgery solutions. These include its dedication to intracranial cases, complete solution integration, industry-leading accuracy, "shrink-wrap" dose conformity and extensive proven clinical efficacy. Demonstrations of the system will emphasize that Perfexion is designed to minimize the risk of human error and radiation toxicity, while optimizing accuracy and dose conformance.
"Collecting, storing and analyzing clinical data are increasingly critical in refining treatments based on outcomes," says Jay Hoey, Executive Vice President, Elekta North America. "Leksell Gamma Knife Registry can serve as the foundation for the clinic's development of evidence-based, personalized medicine protocols that will benefit patients."
Learn more at www.elekta.com/gammaknife.
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,400 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com.
For further information, please contact:
Johan Andersson Melbi, Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, email: email@example.com
Time zone: CET: Central European Time
Michelle Joiner, Director, Global Public Relations and Brand Management, Elekta
Tel: +1 770-670-2447, email: firstname.lastname@example.org
Time zone: ET: Eastern Time